A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.

Part of paid clinical trials in Grayslake, Illinois.

Sponsor
AbbVie
Study ID
NCT07567781
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • ABBV-722 — DRUG
    Oral Tablet
  • Midazolam — DRUG
    Oral Solution
  • Metformin — DRUG
    Oral Tablet
  • Digoxin — DRUG
    Oral Tablet
  • Pitavastatin — DRUG
    Oral Tablet
  • Sitagliptin — DRUG
    Oral Tablet

Study Details

The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin

Key Dates

Start date
Apr 30, 2026
Status verified
Apr 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
12 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Period 1 & 2
    During Period 1, participants will receive a single dose of midazolam, followed by the co-administration of single doses of selected transporter cocktail substrates. Throughout Period 2, participants will receive a schedule of daily single doses of ABBV-722, a combination of single doses of midazolam and ABBV-722, and single doses of Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin combined with a single dose of ABBV-722.

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) [ Time Frame: Up to 56 Days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Acpru /Id# 282184GrayslakeIllinois60030-

Find similar trials in Grayslake, IL

By research site
Acpru· Grayslake, IL

Related Studies